GSK plc files 6-K

GSK plc completed its acquisition of 35Pharma Inc. for $950 million, gaining access to HS235, a novel protein-based therapeutic for pulmonary hypertension. This acquisition aims to expand GSK's respiratory, immunology, and inflammation pipeline with a drug targeting the activin receptor signalling pathway.